Profile data is unavailable for this security.
About the company
J.B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. The Company specializes in gastroenterology, hypertension and dermatology. It is also focused on other therapeutic categories like nephrology, respiratory, virology, diabetes, and nicotine replacement therapy (NRT). The Company is engaged in the business of manufacturing and marketing of a diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients (APIs). Its brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. It specializes in manufacturing medicated and herbal lozenges. It produces hard-candy lozenges, soft-center lozenges and powder-filled lozenges for varied medical needs. Its API products include Diclofenac Sodium, Diclofenac Diethylamine, Diclofenac Acid, Nifedipine, and others. It maintains a direct presence in Russia and South Africa, while leveraging distributor partnerships across the United States, Asia, Africa, and Latin America.
- Revenue in INR (TTM)41.93bn
- Net income in INR7.54bn
- Incorporated1976
- Employees5.52k
- LocationJ B Chemicals and Pharmaceuticals LtdCnergy It Park, Appa Saheb Marathe MargMUMBAI 400025IndiaIND
- Phone+91 2 224822222
- Fax+91 2 224930534
- Websitehttps://jbpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuland Laboratories Ltd | 15.75bn | 1.79bn | 167.22bn | 1.80k | 93.36 | -- | 63.66 | 10.62 | 139.62 | 139.62 | 1,227.57 | -- | -- | -- | -- | 8,755,392.00 | -- | 11.09 | -- | 14.93 | 49.33 | 49.56 | 11.37 | 14.20 | -- | 12.29 | -- | 6.80 | -5.24 | 14.13 | -13.32 | 45.82 | 33.44 | 43.10 |
| Natco Pharma Ltd | 45.60bn | 15.57bn | 182.64bn | 4.20k | 11.73 | -- | 10.15 | 4.01 | 86.94 | 86.94 | 254.62 | -- | -- | -- | -- | 10,860,210.00 | -- | 15.82 | -- | 18.14 | 82.79 | 75.22 | 33.87 | 30.39 | -- | 44.51 | -- | 12.09 | 10.77 | 18.26 | 35.81 | 32.55 | 7.37 | -2.33 |
| Eris Lifesciences Ltd | 30.78bn | 4.31bn | 188.49bn | 3.56k | 43.04 | -- | 24.86 | 6.12 | 31.61 | 31.61 | 225.62 | -- | -- | -- | -- | 8,651,377.00 | -- | 9.98 | -- | 13.50 | 74.64 | 77.74 | 15.28 | 20.85 | -- | 4.06 | -- | -- | 44.02 | 21.92 | -10.24 | 3.48 | 0.4868 | -- |
| Piramal Pharma Ltd | 88.71bn | -1.64bn | 200.98bn | 7.13k | -- | -- | 29.04 | 2.27 | -1.26 | -1.26 | 66.90 | -- | -- | -- | -- | 12,449,300.00 | -- | -- | -- | -- | 64.63 | -- | -1.84 | -- | -- | 0.5519 | -- | -- | 11.99 | -- | 411.39 | -- | -- | -- |
| Wockhardt Ltd | 31.51bn | 220.00m | 211.17bn | 2.30k | 982.23 | -- | 89.86 | 6.70 | 1.32 | 1.32 | 194.54 | -- | -- | -- | -- | 13,723,870.00 | -- | -4.37 | -- | -7.67 | 65.92 | 56.50 | 0.2539 | -11.98 | -- | 1.23 | -- | -- | 7.65 | 1.15 | 89.85 | -- | 16.19 | -- |
| Astrazeneca Pharma India Ltd | 21.77bn | 2.01bn | 217.61bn | 802.00 | 108.29 | -- | 90.09 | 9.99 | 80.38 | 80.38 | 871.22 | -- | -- | -- | -- | 27,150,250.00 | -- | 11.06 | -- | 18.24 | 42.78 | 49.98 | 9.23 | 9.43 | -- | 78.86 | -- | 38.57 | 32.48 | 15.59 | -28.34 | 9.89 | -34.23 | 100.00 |
| Sai Life Sciences Ltd | 21.70bn | 3.33bn | 219.60bn | 3.40k | 67.03 | -- | 44.64 | 10.12 | 15.47 | 15.47 | 100.85 | -- | -- | -- | -- | 6,380,065.00 | -- | -- | -- | -- | 73.41 | -- | 15.34 | -- | -- | 10.74 | -- | -- | 15.66 | -- | 105.45 | -- | -- | -- |
| Pfizer Ltd | 24.82bn | 8.54bn | 221.85bn | 1.60k | 25.99 | -- | 24.30 | 8.94 | 186.60 | 186.60 | 542.67 | -- | -- | -- | -- | 15,533,980.00 | -- | 15.22 | -- | 18.50 | 65.10 | 61.73 | 34.39 | 25.99 | -- | 83.13 | -- | 50.95 | 4.02 | 1.18 | 39.23 | 8.56 | -6.02 | 28.47 |
| Emcure Pharmaceuticals Ltd | 88.50bn | 8.70bn | 268.42bn | 6.73k | 30.84 | -- | 20.64 | 3.03 | 45.91 | 45.91 | 467.02 | -- | -- | -- | -- | 13,148,240.00 | -- | 8.47 | -- | 15.86 | 59.93 | 59.30 | 10.11 | 8.99 | -- | 30.68 | -- | 0.00 | 18.59 | 9.36 | 36.76 | 52.13 | 21.35 | -- |
| Gland Pharma Ltd | 61.13bn | 8.47bn | 274.98bn | 4.35k | 32.46 | -- | 21.86 | 4.50 | 51.42 | 51.42 | 371.01 | -- | -- | -- | -- | 14,049,110.00 | -- | 10.77 | -- | 11.98 | 65.00 | 57.00 | 13.86 | 19.59 | -- | 34.31 | -- | 14.03 | -0.8512 | 16.36 | -9.57 | -2.00 | 15.15 | -- |
| J B Chemicals and Pharmaceuticals Ltd | 41.93bn | 7.54bn | 329.61bn | 5.52k | 43.28 | -- | 35.34 | 7.86 | 47.44 | 47.44 | 263.86 | -- | -- | -- | -- | 7,600,215.00 | -- | 15.91 | -- | 19.18 | 67.95 | 62.00 | 17.98 | 16.36 | -- | 164.76 | -- | 33.55 | 12.45 | 17.16 | 19.35 | 19.53 | 10.52 | 23.03 |
| Anthem BioSciences Ltd | 19.97bn | 4.85bn | 372.53bn | 2.06k | 77.21 | -- | 61.11 | 18.66 | 8.59 | 8.59 | 35.40 | -- | -- | -- | -- | 9,682,764.00 | -- | -- | -- | -- | 61.25 | -- | 24.27 | -- | -- | -- | -- | -- | 29.96 | -- | 22.86 | -- | -- | -- |
| Ajanta Pharma Ltd | 52.02bn | 10.15bn | 373.81bn | 9.63k | 36.84 | -- | 31.62 | 7.19 | 81.21 | 81.21 | 416.34 | -- | -- | -- | -- | 5,402,607.00 | -- | 17.31 | -- | 21.48 | 77.65 | 73.83 | 19.50 | 19.60 | -- | 96.70 | -- | 33.78 | 10.44 | 12.43 | 12.77 | 14.50 | 5.84 | 26.43 |
| IPCA Laboratories Ltd | 95.05bn | 9.10bn | 379.08bn | 18.04k | 41.66 | -- | 27.90 | 3.99 | 35.86 | 35.86 | 374.66 | -- | -- | -- | -- | 5,267,716.00 | -- | 9.16 | -- | 12.39 | 70.13 | 60.24 | 9.97 | 11.25 | -- | 19.58 | -- | 13.42 | 16.02 | 13.97 | 34.77 | 4.00 | 20.42 | 9.86 |
| GlaxoSmithKline Pharmaceuticals Ltd | 38.01bn | 10.21bn | 426.45bn | 3.11k | 41.77 | -- | 39.16 | 11.22 | 60.26 | 60.26 | 224.34 | -- | -- | -- | -- | 12,209,250.00 | -- | 15.30 | -- | 25.66 | 64.24 | 56.70 | 26.86 | 16.77 | -- | 452.52 | -- | 144.35 | 8.56 | 3.06 | 57.23 | 53.14 | -31.03 | 16.00 |
Data as of Mar 06 2026. Currency figures normalised to J B Chemicals and Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
21.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Jan 2026 | 7.00m | 4.37% |
| Axis Asset Management Co. Ltd.as of 15 Feb 2026 | 6.00m | 3.74% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Jan 2026 | 3.68m | 2.30% |
| Abrdn Asia Ltd.as of 25 Feb 2026 | 3.51m | 2.19% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 3.29m | 2.05% |
| Norges Bank Investment Managementas of 30 Sep 2025 | 2.95m | 1.84% |
| Franklin Templeton Asset Management (India) Pvt Ltd.as of 30 Jan 2026 | 2.57m | 1.60% |
| Canara Robeco Asset Management Co., Ltd. (Invt Mgmt)as of 31 Jan 2026 | 2.05m | 1.28% |
| WhiteOak Capital Asset Management Ltd.as of 31 Jan 2026 | 1.44m | 0.90% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 1.42m | 0.88% |
More ▼
Data from 31 Dec 2025 - 26 Feb 2026Source: FactSet Research Systems Inc.
